DESIGN OF A RANDOMIZED PHASE 2B, PLACEBO-CONTROLLED TRIAL ASSESSING SAFETY AND EFFICACY OF AD04 IN EARLY ALZHEIMER&#39;S DISEASE (&quot;ADVANCE&quot;)

ondansetron ultra-low dose (AD04) - Adial

alhydrogel injectable (AD04) - ADvantage Therap

https://cslide.ctimeetingtech.com/global_storage/media/content/adpd24/ADPD24_-_Posters_for_website_NOV_23.pdf

Benjamin Haaland1,2; Sam Dickson3; Joshua Christensen3; Agustín Fernández-Fernández4; Timo Grimmer5; Oliver Peters6; Suzanne Hendrix7; Achim Schneeberger8

Feb 16, 2024